Tim Schmeiser

1.0k total citations
21 papers, 277 citations indexed

About

Tim Schmeiser is a scholar working on Pathology and Forensic Medicine, Infectious Diseases and Neurology. According to data from OpenAlex, Tim Schmeiser has authored 21 papers receiving a total of 277 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pathology and Forensic Medicine, 6 papers in Infectious Diseases and 5 papers in Neurology. Recurrent topics in Tim Schmeiser's work include Systemic Sclerosis and Related Diseases (7 papers), Long-Term Effects of COVID-19 (5 papers) and COVID-19 Clinical Research Studies (4 papers). Tim Schmeiser is often cited by papers focused on Systemic Sclerosis and Related Diseases (7 papers), Long-Term Effects of COVID-19 (5 papers) and COVID-19 Clinical Research Studies (4 papers). Tim Schmeiser collaborates with scholars based in Germany, United Kingdom and Spain. Tim Schmeiser's co-authors include Ulf Müller‐Ladner, Jutta Richter, Christof Specker, Bimba F. Hoyer, Hendrik Schulze‐Koops, Reinhard Voll, Anja Strangfeld, Ulf Müeller-Ladner, Rebecca Hasseli and Alexander Pfeil and has published in prestigious journals such as Annals of the Rheumatic Diseases, Toxicology in Vitro and European Journal of Internal Medicine.

In The Last Decade

Tim Schmeiser

19 papers receiving 272 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tim Schmeiser Germany 9 120 81 65 61 54 21 277
Lucrezia Verardi Italy 6 48 0.4× 40 0.5× 34 0.5× 31 0.5× 25 0.5× 15 167
Michael Gernert Germany 10 95 0.8× 42 0.5× 21 0.3× 79 1.3× 30 0.6× 34 295
J.-C. Balblanc France 8 36 0.3× 167 2.1× 25 0.4× 112 1.8× 136 2.5× 12 351
Annelies Stockman Belgium 8 58 0.5× 17 0.2× 55 0.8× 33 0.5× 35 0.6× 16 258
Frédérick Durand United States 9 33 0.3× 23 0.3× 60 0.9× 141 2.3× 23 0.4× 31 333
Silvia Balduzzi Italy 7 18 0.1× 75 0.9× 40 0.6× 58 1.0× 40 0.7× 11 172
Teresa Baudrier Portugal 10 33 0.3× 18 0.2× 56 0.9× 53 0.9× 9 0.2× 34 199
Akito Hasegawa Japan 8 41 0.3× 14 0.2× 30 0.5× 40 0.7× 7 0.1× 33 215
Mahboubeh Mansouri Iran 12 33 0.3× 13 0.2× 63 1.0× 49 0.8× 10 0.2× 40 346
Claudia Lasagni Italy 12 28 0.2× 21 0.3× 170 2.6× 30 0.5× 11 0.2× 28 325

Countries citing papers authored by Tim Schmeiser

Since Specialization
Citations

This map shows the geographic impact of Tim Schmeiser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tim Schmeiser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tim Schmeiser more than expected).

Fields of papers citing papers by Tim Schmeiser

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tim Schmeiser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tim Schmeiser. The network helps show where Tim Schmeiser may publish in the future.

Co-authorship network of co-authors of Tim Schmeiser

This figure shows the co-authorship network connecting the top 25 collaborators of Tim Schmeiser. A scholar is included among the top collaborators of Tim Schmeiser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tim Schmeiser. Tim Schmeiser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bergmann, Christina, Gabriela Riemekasten, Jeska K de Vries‐Bouwstra, et al.. (2024). OP0013 ANTI-Ro/SSA ANTIBODIES ARE PREDICTIVE OF A MORE SEVERE LUNG INVOLVEMENT IN PATIENTS WITH SYSTEMIC SCLEROSIS: A STUDY FROM THE EUSTAR HDATABASE. Annals of the Rheumatic Diseases. 83. 1–2. 2 indexed citations
2.
Hasseli, Rebecca, Ulf Müeller-Ladner, Bimba F. Hoyer, et al.. (2021). Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases. RMD Open. 7(1). e001464–e001464. 66 indexed citations
3.
Hasseli, Rebecca, Alexander Pfeil, Andreas Krause, et al.. (2021). A survey to evaluate knowledge, perceptions and attitudes toward COVID-19 vaccinations among rheumatologists in Germany. Rheumatology International. 41(11). 1949–1956. 3 indexed citations
4.
Regierer, Anne C., Rebecca Hasseli, Martin Schäfer, et al.. (2021). TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD. RMD Open. 7(3). e001896–e001896. 17 indexed citations
5.
Hasseli, Rebecca, Alexander Pfeil, Bimba F. Hoyer, et al.. (2021). Deutsches Register www.Covid19-Rheuma.de. Zeitschrift für Rheumatologie. 80(7). 641–646.
6.
Hasseli, Rebecca, Ulf Müller‐Ladner, Tim Schmeiser, et al.. (2021). POS1261 DISEASE ACTIVITY AND PAIN LEVELS ARE NOT INFLUENCED BY THE CURRENT COVID19 PANDEMIC IN PATIENTS WITH RHEUMATIC DISEASES IN GERMANY – DATA FROM THE GERMAN COVID-19 PATIENT SURVEY. Annals of the Rheumatic Diseases. 80. 915–915. 1 indexed citations
7.
Strangfeld, Anja, et al.. (2021). OP0116 ELDERLY PATIENTS ARE NOT AT INCREASED RISK OF SERIOUS INFECTIONS WHEN RECEIVING BDMARDS OR JAK INHIBITORS COMPARED TO CSDMARD TREATMENT. Annals of the Rheumatic Diseases. 80(Suppl 1). 64.2–65. 5 indexed citations
8.
9.
10.
Ndosi, Mwidimi, Begonya Alcacer‐Pitarch, Yannick Allanore, et al.. (2018). Common measure of quality of life for people with systemic sclerosis across seven European countries: a cross-sectional study. Annals of the Rheumatic Diseases. 77(7). 1032–1038. 13 indexed citations
11.
Tarner, Ingo H., et al.. (2018). Facettenreichtum des Morbus Whipple. Zeitschrift für Rheumatologie. 78(1). 55–65.
12.
Schmeiser, Tim, et al.. (2011). Arthritis in patients with systemic sclerosis. European Journal of Internal Medicine. 23(1). e25–e29. 27 indexed citations
13.
Schmeiser, Tim, P. Saar, A. Müller, et al.. (2011). Profile of gastrointestinal involvement in patients with systemic sclerosis. Rheumatology International. 32(8). 2471–2478. 44 indexed citations
14.
Schmeiser, Tim & Ulf Müller‐Ladner. (2009). EULAR-Empfehlungen zur Behandlung der systemischen Sklerose. Zeitschrift für Rheumatologie. 69(1). 87–92. 2 indexed citations
15.
Hofgärtner, F., et al.. (2008). Rechtsventrikulärer Thrombus nach Schrittmacherimplantation bei sekundärem Antiphospholipid-Syndrom. DMW - Deutsche Medizinische Wochenschrift. 123(01/02). 12–16. 1 indexed citations
16.
Manetti, Mirko, Elena Neumann, A. Müller, et al.. (2008). Endothelial/lymphocyte activation leads to prominent CD4+ T cell infiltration in the gastric mucosa of patients with systemic sclerosis. Arthritis & Rheumatism. 58(9). 2866–2873. 42 indexed citations
17.
Saar, P., Tim Schmeiser, Ingo H. Tarner, & Ulf Müller‐Ladner. (2007). Gastrointestinale Beteiligung bei systemischer Sklerose. Der Hautarzt. 58(10). 844–850. 4 indexed citations
18.
Mersch‐Sundermann, Volker, Theeshan Bahorun, T. Stahl, et al.. (2006). Assessment of the DNA damaging potency and chemopreventive effects towards BaP-induced genotoxicity in human derived cells by Monimiastrum globosum, an endemic Mauritian plant. Toxicology in Vitro. 20(8). 1427–1434. 11 indexed citations
19.
Anger, B., Tim Schmeiser, H. Heimpel, et al.. (1990). Evaluation von 196 Patienten mit chronischer myeloischer Leukämie anhand eines Standard-Prognose-Modells. Oncology Research and Treatment. 13(2). 109–114. 1 indexed citations
20.
Kurrle, E. & Tim Schmeiser. (1984). Diagnostik, Prävention und Behandlung von Infekten bakterieller, mykotischer und viraler Genese bei abwehrgeschwächten Patienten. Oncology Research and Treatment. 7(1). 37–45. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lucrezia Verardi Breakdown of academic impact, for papers by Michael Gernert Breakdown of academic impact, for papers by J.-C. Balblanc Breakdown of academic impact, for papers by Annelies Stockman Breakdown of academic impact, for papers by Frédérick Durand Breakdown of academic impact, for papers by Silvia Balduzzi Breakdown of academic impact, for papers by Teresa Baudrier Breakdown of academic impact, for papers by Akito Hasegawa Breakdown of academic impact, for papers by Mahboubeh Mansouri Breakdown of academic impact, for papers by Claudia Lasagni
Rankless by CCL
2026